,
Lhomme, Edouard http://orcid.org/0000-0003-0214-1694
Modet, Camara
Augier, Augustin
Faye, Sylvain
Dabakuyo-Yonli, Tienhan Sandrine
Levy-Marchal, Claire
D’Ortenzio, Eric
Yazdanpanah, Yazdan
Chêne, Geneviève
Beavogui, Abdoul Habib
Richert, Laura
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases
London School of Hygiene and Tropical Medicine
Institut national de la santé et de la recherche médicale
Article History
Received: 1 October 2018
Accepted: 3 June 2019
First Online: 11 July 2019
Ethics approval and consent to participate
: The legal sponsor of the trial in Guinea is the French Institut national de la santé et de la recherche médicale (Inserm).The clinical trial protocol has been approved by the Inserm institutional review board and the Guinean national ethics committee (Comité National d’Ethique pour la Recherche en Santé) for the conduct of the PREVAC trial in Guinea.
: The clinical trial was conducted with the support of Janssen, Bavarian Nordic, and Merck Sharp & Dohme Corp. (MSD), who provided the vaccines.YY declares that he has been a board member receiving consultancy fees from AbbVie, Bristol-Myers Squibb, Gilead, MSD, Johnson & Johnson, Pfizer, and ViiV Healthcare in the past 4 years outside the subjects of the meetings (on HIV and HCV mostly); however, all these activities were stopped in November 2016.The other authors declare that they have no competing interests.